| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jonathan Galli | Q90482229 |
| P2093 | author name string | John Greenlee | |
| P2860 | cites work | New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity | Q73546523 |
| Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors | Q73726050 | ||
| Anti-amphiphysin associated limbic encephalitis: a paraneoplastic presentation of small-cell lung carcinoma | Q74813549 | ||
| Neurophysiological diagnosis of acquired sensory ganglionopathies | Q79125934 | ||
| Successful treatment of paraneoplastic cerebellar degeneration with Rituximab | Q81412009 | ||
| Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity | Q88428005 | ||
| Paraneoplastic striatal encephalitis and myelitis associated with anti-CV2/CRMP-5 antibodies in a patient with small cell lung cancer | Q88735356 | ||
| Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies | Q89094817 | ||
| Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis | Q91585663 | ||
| Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2 | Q91890279 | ||
| Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat | Q24297060 | ||
| Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis | Q24614608 | ||
| Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis | Q24620536 | ||
| The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project | Q24621267 | ||
| Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma | Q24653500 | ||
| Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers | Q27309823 | ||
| Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review | Q28080165 | ||
| Recognizing Autoimmune-Mediated Encephalitis in the Differential Diagnosis of Limbic Disorders | Q28087810 | ||
| Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration | Q28142447 | ||
| Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen | Q28300922 | ||
| Sensory neuronopathies | Q30278525 | ||
| Therapeutic plasma exchange in neurology: 2012. | Q30415046 | ||
| Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe | Q72331467 | ||
| Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. | Q30587642 | ||
| Limbic encephalitis and variants: classification, diagnosis and treatment. | Q31127230 | ||
| Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor | Q33179400 | ||
| Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor | Q33601343 | ||
| Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges | Q33857841 | ||
| Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients | Q33907001 | ||
| Paraneoplastic syndromes of the spinal cord, nerve, and muscle | Q34096509 | ||
| Purkinje Cell Death After Uptake of Anti-Yo Antibodies in Cerebellar Slice Cultures | Q34222496 | ||
| Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome | Q34225761 | ||
| Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients | Q34233970 | ||
| Acute cerebellar ataxia, acute cerebellitis, and opsoclonus-myoclonus syndrome | Q34340349 | ||
| In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. | Q34408200 | ||
| Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. | Q34476604 | ||
| Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis | Q34507534 | ||
| Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus | Q34512965 | ||
| Anti‐neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments | Q34533380 | ||
| Management of paraneoplastic neurological syndromes: report of an EFNS Task Force | Q34546579 | ||
| Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. | Q34575117 | ||
| Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice | Q34842262 | ||
| Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. | Q34911466 | ||
| AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. | Q34972785 | ||
| Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature | Q35162221 | ||
| Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies | Q35194421 | ||
| Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. | Q35456681 | ||
| Immunomodulatory treatment trial for paraneoplastic neurological disorders | Q35800688 | ||
| No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies | Q35880899 | ||
| Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies | Q36048199 | ||
| Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. | Q36143265 | ||
| Managing paraneoplastic neurological disorders | Q36426616 | ||
| A clinical approach to diagnosis of autoimmune encephalitis. | Q37343730 | ||
| Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues | Q37889027 | ||
| Paraneoplastic cerebellar degeneration. | Q37914399 | ||
| Paraneoplastic myelopathy | Q38063034 | ||
| Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort | Q38415730 | ||
| Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies | Q38678032 | ||
| Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. | Q38726369 | ||
| Limbic Encephalitis Associated With GAD65 Antibodies: Brief Review of the Relevant literature | Q38794169 | ||
| Voltage-gated potassium channel-complex autoimmunity and associated clinical syndromes | Q38817071 | ||
| NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture | Q39030050 | ||
| Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System | Q39180685 | ||
| Autoantibodies in childhood opsoclonus-myoclonus syndrome | Q39952944 | ||
| Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. | Q40154528 | ||
| Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients | Q40708054 | ||
| Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport | Q41250998 | ||
| The role of antibody in recovery from alphavirus encephalitis | Q41672969 | ||
| Electroencephalographic Evaluation for Early Diagnosis of Limbic Encephalitis | Q42186007 | ||
| Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma | Q42455170 | ||
| Successful immunosuppressive treatment and long-term follow-up of anti-Ri-associated paraneoplastic myelitis | Q42718474 | ||
| Treatment of paraneoplastic neurologic disorders | Q42907014 | ||
| Effect of plasmapheresis on serum and CSF autoantibody levels in CNS paraneoplastic syndromes | Q44459447 | ||
| Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy | Q45024086 | ||
| Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. | Q45902843 | ||
| Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice | Q46200846 | ||
| Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration | Q47211573 | ||
| Autoimmune Encephalitis Epidemiology and a comparison to Infectious Encephalitis. | Q47239243 | ||
| Clinical analysis of anti-Ma2-associated encephalitis. | Q47296724 | ||
| Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. | Q47824946 | ||
| Paraneoplastic brain stem encephalitis | Q48178232 | ||
| Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. | Q48301180 | ||
| Cerebellar degeneration with Hodgkin disease. An immunological study | Q48367107 | ||
| T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. | Q48370665 | ||
| Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. | Q48400480 | ||
| Anti-Hu-associated brainstem encephalitis | Q48823692 | ||
| Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration | Q48949272 | ||
| Antibody types and IgG subclasses in paraneoplastic neurological syndromes | Q48959487 | ||
| GAD65 neurological autoimmunity. | Q51210635 | ||
| Subacute cerebellar degeneration associated with neoplasms | Q51248276 | ||
| Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. | Q51693450 | ||
| No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes. | Q51791725 | ||
| Pathogenic potential of antibodies to the GABAB receptor. | Q55191483 | ||
| Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis | Q57159490 | ||
| Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men | Q57255803 | ||
| Motor neuron syndromes in cancer patients | Q57256406 | ||
| Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites | Q57256456 | ||
| Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies | Q59697819 | ||
| Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis | Q64106156 | ||
| The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. | Q64892080 | ||
| The distinctive clinical features of paraneoplastic sensory neuronopathy | Q67904239 | ||
| Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro | Q70514588 | ||
| Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption | Q71876994 | ||
| Immunological and Clinical Response to Immunosuppressive Treatment in Paraneoplastic Cerebellar Degeneration | Q71970502 | ||
| Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein | Q71977729 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | neoplasm | Q1216998 |
| P577 | publication date | 2020-03-06 | |
| P1433 | published in | F1000Research | Q27701587 |
| P1476 | title | Paraneoplastic Diseases of the Central Nervous System | |
| P478 | volume | 9 |
| Q101119022 | A Scoping Review on Paraneoplastic Autoimmune Limbic Encephalitis (PALE) Psychiatric Manifestations |
| Q97521459 | Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications |
Search more.